![炎癥介質(zhì)與抗炎藥物_第1頁](http://file4.renrendoc.com/view10/M03/27/20/wKhkGWWWI9eAZtgwAAA8RzKgl_0844.jpg)
![炎癥介質(zhì)與抗炎藥物_第2頁](http://file4.renrendoc.com/view10/M03/27/20/wKhkGWWWI9eAZtgwAAA8RzKgl_08442.jpg)
![炎癥介質(zhì)與抗炎藥物_第3頁](http://file4.renrendoc.com/view10/M03/27/20/wKhkGWWWI9eAZtgwAAA8RzKgl_08443.jpg)
![炎癥介質(zhì)與抗炎藥物_第4頁](http://file4.renrendoc.com/view10/M03/27/20/wKhkGWWWI9eAZtgwAAA8RzKgl_08444.jpg)
![炎癥介質(zhì)與抗炎藥物_第5頁](http://file4.renrendoc.com/view10/M03/27/20/wKhkGWWWI9eAZtgwAAA8RzKgl_08445.jpg)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
炎癥介質(zhì)與抗炎藥物Inflammation(炎癥)Theclassicalsignsofinflammationareredness,swelling,heat,pain,andlossoffunction.
SkinabscessPneumoniaTheProcessofInflammation1.Initiationoftheeventbyaforeignsubstanceorphysicalinjury2.Recruitmentandchemoattractionofinflammatorycells,andactivationofthesecells3.Releaseinflammatorymediatorscapableofdamagingorkillinganinvadingmicrobeortumor.Insomeinstances,theinflammatoryresponseisinitiatedbyanotherwiseharmlessforeignmaterial(e.g.,pollen).Inflammationcanalsoresultfromanautoimmuneresponsetothehost’sowntissue,asoccursinrheumatoidarthritis.Whydoweneedanti-inflammatorydrugs?Inmostcases,theinflammatoryresponseeventuallysubsides,butifsuchaself-limitingregulationdoesnotoccur,theinflammatoryresponsewillrequirepharmacologicalintervention.Theneedforanti-inflammatorydrugsariseswhentheinflammatoryresponseisinappropriate,aberrant,sustained,orcausesdestructionoftissue.Hosttissuemayundergoinjury,sincemanyoftheinflammatorymediatorsarenotspecificforaparticulartissuetarget.THEINFLAMMATORYPROCESSThephasesofinflammatoryresponsesRapidphase:secondstominutes,consistingofvasodilation,increasedbloodflow,edema,andpain.Chronicphase:overmonthstoyears;dramaticallyincreasedproductionofinflammatorymediators.AsthmaSecondarychronicphaseofinflammation:afteryearsofoxidativedamagehasdegradedbloodvesselsandtissues.Suchchronicinflammationappearstoplayaroleinmanydiseasestates,suchasarteriosclerosisandcancer.動(dòng)脈硬化InflammatoryMediatorsEicosanoids類花生酸Theeicosanoids,derivedfroma20-carbonunsaturatedfattyacid,arachidonicacid(eicosatetraenoicacid),areobtainedfrommembranephospholipidsandsynthesizeddenovoatthetimeofcellularstimulation.ArachidonateMetabolismPathways
Phospholipids
ArachidonicAcid
COX-2COX-1Oldanti-inflammatorydrugtarget
ProstaglandinH2
PGI2
PGF2α
PGE2PGD2TXA2
PhospholipaseA2PGESPGES:prostaglandinEsynthase,anewanti-inflammatorydrugtargetPGDH15-keto-PGE2Cyclooxygenase(COX)Twoisoforms:COX-1:Constitutiveor“housekeeping”isoformthatisresponsibleforthebasalproductionofprostaglandins,prostacyclins,andthromboxanes.COX-2:Induciblebycytokinesandotherinflammatorystimuliandisbelievedtopredominateduringchronicinflammation.ThefinalproductoftheCOXpathwayistissuespecific.Forexample,plateletsproducethromboxaneA2(TxA2);vascularendothelialcellsproduceprostacyclin(PGI2);mastcellsproduceprostaglandinD2(PGD2);COX-2selectiveinhibitorssuperiortonon-selectiveinhibitors?15-ProstaglandinDehydrogenaseCOX-2and15-PGDHapricoxibNONSTEROIDALANTIINFLAMMATORY
DRUGS(NSAIDs)Thenonsteroidalanti-inflammatorydrugs(NSAIDs)haveavarietyofclinicalusesasantipyretics,analgesics,andanti-inflammatoryagents.Unliketheopioidanalgesics,theydonotcauseneurologicaldepressionordependence.NSAIDsreducepainandinflammationassociatedwithrheumatoiddiseasesbutdonotdelayorreversethedisease’sprogress.MechanismofAction
Theanti-inflammatoryactionsoftheNSAIDsaremostlikelyexplainedbytheirinhibitionofprostaglandinsynthesisbyCOX-2.TheCOX-2isoformisthepredominantCOXinvolvedintheproductionofprostaglandinsduringinflammatoryprocesses.ProstaglandinsoftheEandFseriesevokesomeofthelocalandsystemicmanifestationsofinflammation,suchasvasodilation,hyperemia,increasedvascularpermeability,swelling,pain,andincreasedleukocytemigration.AdverseEffectsofNSAIDs
AnumberofthetoxicitiescommonlycausedbytheNSAIDsresultfromtheinhibitionofprostaglandinsynthesis.TheabilityofNSAIDstoincreasegastricacidsecretionandinhibitbloodclottingcanleadtoGItoxicity.BiologicalOxidantsThebiologicallyderivedoxidantsarepotentbacterialkillersbutarealsoamajorcontributingfactorintissueinjurythatresultsfromtheinflammatoryresponse.Theseoxidantsincludethesuperoxideanion(?O2-),hydrogenperoxide(H2O2),nitricoxide(NO),peroxynitrite(OONO),hypochlorousacid(HOClTheseoxidants,largelygeneratedbyphagocyticcellssuchasneutrophilsandmacrophages,inducetissueinjurybeyondthatproducedbydigestiveenzymesandeicosanoids.Inhibitionofproductionoftheseoxidantsorinactivationofthesesubstancesbyantioxidantsisanimportantstrategyforthetreatmentofinflammatorydisorders.CytokinesTNF-andIL-1areproducedprimarilybycellsofthemonocyte–macrophagelineage.Theyworkinconcerttostimulateinflammatoryresponsessuchaspain,fever,andtherecruitmentoflymphocytes.Inaddition,theyinduceproductionofmanyotherinflammatorymediatorsandcontributetothetissuedamageseeninchronicinflammation.ApproximatelyonemillionindividualsworldwideareeitherundergoingtreatmentorhavebeentreatedwithTNFinhibitorsavailableinthepharmaceuticalmarket,encompassingindicationsthatincluderheumatoidarthritis,psoriaticarthritis牛皮癬性關(guān)節(jié)炎,psoriasis銀屑病andinflammatoryboweldiseases炎癥性腸病糖皮質(zhì)激素(Glucocorticoid),又名“腎上腺皮質(zhì)激素”,是由腎上腺皮質(zhì)分泌的一類甾體激素
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 醫(yī)療器械工程居間合同范本
- 施工電梯布置專項(xiàng)方案
- 食品安全風(fēng)險(xiǎn)評(píng)估與管理技術(shù)作業(yè)指導(dǎo)書
- 承包山林合同書
- 市場(chǎng)營銷策略制定與實(shí)施作業(yè)指導(dǎo)書
- 停車場(chǎng)管理服務(wù)合同
- 住房和城鄉(xiāng)建設(shè)委員會(huì)
- 林業(yè)經(jīng)濟(jì)管理與政策作業(yè)指導(dǎo)書
- 雞舍租賃合同
- 技術(shù)服務(wù)合同格式
- 2024統(tǒng)編版初中八年級(jí)語文上冊(cè)第五單元:大單元整體教學(xué)設(shè)計(jì)
- 小記者新聞寫作培訓(xùn)
- 【《智慧城市建設(shè)中電子政務(wù)建設(shè)問題及完善策略一以瀘州市為例》9000字(論文)】
- IPO項(xiàng)目盡職調(diào)查清單(詳細(xì))
- ETL開發(fā)工程師招聘面試題及回答建議2025年
- DB11T 1136-2023 城鎮(zhèn)燃?xì)夤艿婪D(zhuǎn)內(nèi)襯修復(fù)工程施工及驗(yàn)收規(guī)程
- 2025屆浙江省兩校高一數(shù)學(xué)第一學(xué)期期末質(zhì)量檢測(cè)試題含解析
- 肝硬化肝性腦病診療指南(2024年版)解讀
- 零部件測(cè)繪與 CAD成圖技術(shù)(中職組)沖壓機(jī)任務(wù)書
- 2024年騎電動(dòng)車撞傷人私了協(xié)議書范文
- 四年級(jí)數(shù)學(xué)(上)計(jì)算題專項(xiàng)練習(xí)及答案
評(píng)論
0/150
提交評(píng)論